Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $89.67 million. The enterprise value is $79.49 million.
Important Dates
The next confirmed earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 228.45 million shares outstanding. The number of shares has increased by 38.50% in one year.
| Current Share Class | 228.45M |
| Shares Outstanding | 228.45M |
| Shares Change (YoY) | +38.50% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 0.95% |
| Owned by Institutions (%) | 9.90% |
| Float | 226.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.07 |
| Forward PS | 3.33 |
| PB Ratio | 2.64 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.60, with a Debt / Equity ratio of 0.58.
| Current Ratio | 0.60 |
| Quick Ratio | 0.57 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.22 |
Financial Efficiency
Return on equity (ROE) is -100.35% and return on invested capital (ROIC) is -44.75%.
| Return on Equity (ROE) | -100.35% |
| Return on Assets (ROA) | -24.97% |
| Return on Invested Capital (ROIC) | -44.75% |
| Return on Capital Employed (ROCE) | -120.12% |
| Revenue Per Employee | $768,800 |
| Profits Per Employee | -$539,448 |
| Employee Count | 105 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $309,000 in taxes.
| Income Tax | 309,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.85% in the last 52 weeks. The beta is 0.89, so Vaxart's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -43.85% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 64.94 |
| Average Volume (20 Days) | 606,844 |
Short Selling Information
The latest short interest is 21.17 million, so 9.27% of the outstanding shares have been sold short.
| Short Interest | 21.17M |
| Short Previous Month | 14.68M |
| Short % of Shares Out | 9.27% |
| Short % of Float | 9.36% |
| Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, Vaxart had revenue of $80.72 million and -$56.64 million in losses. Loss per share was -$0.25.
| Revenue | 80.72M |
| Gross Profit | -37.48M |
| Operating Income | -55.51M |
| Pretax Income | -56.33M |
| Net Income | -56.64M |
| EBITDA | -46.60M |
| EBIT | -55.51M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $26.27 million in cash and $19.02 million in debt, giving a net cash position of $7.25 million or $0.03 per share.
| Cash & Cash Equivalents | 26.27M |
| Total Debt | 19.02M |
| Net Cash | 7.25M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | 32.88M |
| Book Value Per Share | 0.14 |
| Working Capital | -47.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$37.09 million and capital expenditures -$80,000, giving a free cash flow of -$37.17 million.
| Operating Cash Flow | -37.09M |
| Capital Expenditures | -80,000 |
| Free Cash Flow | -37.17M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is -46.42%, with operating and profit margins of -68.76% and -70.17%.
| Gross Margin | -46.42% |
| Operating Margin | -68.76% |
| Pretax Margin | -69.78% |
| Profit Margin | -70.17% |
| EBITDA Margin | -57.73% |
| EBIT Margin | -68.76% |
| FCF Margin | n/a |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.50% |
| Shareholder Yield | -38.50% |
| Earnings Yield | -65.30% |
| FCF Yield | -42.85% |
Dividend DetailsAnalyst Forecast
The average price target for Vaxart is $2.00, which is 409.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 409.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 29.19% |
| EPS Growth Forecast (5Y) | 0.02% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -4.64 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.64 |
| Piotroski F-Score | 4 |
